A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Botanix Pharmaceuticals
- 01 Aug 2019 According to a Botanix Pharmaceuticals media release, enrolment expected to complete in 4Q CY2019.
- 16 May 2019 Planned primary completion date changed from 26 Mar 2020 to 20 Feb 2020.
- 16 May 2019 Status changed from not yet recruiting to recruiting.